

Instance: composition-en-7abe5e4c0a96659ff75905a068c8e8d2
InstanceOf: CompositionUvEpi
Title: "Composition for imjudo Package Leaflet"
Description:  "Composition for imjudo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6d641aa5ef0fae66233e33e585fa5fd8)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - imjudo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What IMJUDO is and what it is used for </li>
<li>What you need to know before you are given IMJUDO</li>
<li>How you are given IMJUDO</li>
<li>Possible side effects </li>
<li>How to store IMJUDO</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What imjudo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What imjudo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>IMJUDO is an anti-cancer medicine. It contains the active substance tremelimumab, which is a type of 
medicine called a monoclonal antibody. This medicine is designed to recognise a specific target 
substance in the body. IMJUDO works by helping your immune system fight your cancer.
IMJUDO in combination with durvalumab is used to treat a type of liver cancer, called advanced or 
unresectable hepatocellular carcinoma (HCC). It is used when your HCC: </p>
<p>cannot be removed by surgery (unresectable), and</p>
<p>may have spread within your liver or to other parts of the body. 
IMJUDO is used to treat a type of lung cancer called advanced non-small cell lung cancer in adults. It 
will be used in combination with other anti-cancer medicines (durvalumab and chemotherapy).
As IMJUDO will be given in combination with other anti-cancer medicines, it is important that you 
also read the package leaflet for these other medicines. If you have any questions about these 
medicines, ask your doctor.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take imjudo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take imjudo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You should not be given IMJUDO
if you are allergic to tremelimumab or any of the other ingredients of this medicine (listed in section 
6). Talk to your doctor if you are not sure.
Warnings and precautions 
Talk to your doctor before you are given IMJUDO if:</p>
<p>you have an autoimmune disease (an illness where the body s immune system attacks its own 
cells)</p>
<p>you have had an organ transplant</p>
<p>you have lung or breathing problems</p>
<p>you have liver problems.
Talk to your doctor before you are given IMJUDO if any of these could apply to you.
When you are given IMJUDO, you can have some serious side effects.
Your doctor may give you other medicines that prevent more severe complications and to help reduce 
your symptoms. Your doctor may delay the next dose of IMJUDO or stop your treatment with 
IMJUDO. Talk to your doctor straight away if you get any of the following side effects:</p>
<p>new or worsening cough; shortness of breath; chest pain (may be signs of lung inflammation)</p>
<p>feeling sick (nausea) or vomiting; feeling less hungry; pain on the right side of your stomach; 
yellowing of skin or whites of eyes; drowsiness; dark urine or bleeding or bruising more easily 
than normal may be signs of liver inflammation)</p>
<p>diarrhoea or more bowel movements than usual; stools that are black, tarry or sticky with blood 
or mucus; severe stomach pain or tenderness (may be signs of bowel inflammation, or a hole in 
the bowel)</p>
<p>fast heart rate; extreme tiredness; weight gain or weight loss; dizziness or fainting; hair loss; 
feeling cold; constipation; headaches that will not go away or unusual headaches (may be signs 
of glands being inflamed, especially the thyroid, adrenal, pituitary or pancreas)</p>
<p>feeling more hungry or thirsty than usual; passing urine more often than usual; high blood sugar; 
fast and deep breathing; confusion; a sweet smell to your breath; a sweet or metallic taste in your 
mouth or a different odour to your urine or sweat (may be signs of diabetes)</p>
<p>decrease in the amount of urine you pass (may be sign of kidney inflammation)</p>
<p>rash; itching; skin blistering or ulcers in the mouth or on other moist surfaces (may be signs of
skin inflammation)</p>
<p>chest pain; shortness of breath; irregular heartbeat (may be signs of heart muscle inflammation)</p>
<p>muscle pain or weakness or rapid tiring of the muscles (may be signs of inflammation or other 
problems of the muscles)</p>
<p>chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness or fever 
(may be signs of infusion-related reactions)</p>
<p>seizures; neck stiffness; headache; fever, chills; vomiting; eye sensitivity to light; confusion and 
sleepiness (may be signs of inflammation of the brain or the membrane around the brain and 
spinal cord)</p>
<p>pain; weakness and paralysis in the hands, feet or arms (may be signs of inflammation of the 
nerves, Guillain-Barr  syndrome)</p>
<p>bleeding (from the nose or gums) and/or bruising (may be signs of low blood platelets).
Talk to your doctor straight away if you have any of the symptoms listed above. 
Children and adolescents
IMJUDO should not be given to children and adolescents below 18 years of age as it has not been 
studied in these patients.
Other medicines and IMJUDO
Tell your doctor if you are taking, have recently taken or might take any other medicines. This 
includes herbal medicines and medicines obtained without a prescription. 
Pregnancy and fertility
This medicine is not recommended during pregnancy. Tell your doctor if you are pregnant, think 
you may be pregnant or are planning to have a baby. If you are a woman who could become pregnant, 
you must use effective contraception while you are being treated with IMJUDO and for at least 3 
months after your last dose.
Breast-feeding
Tell your doctor if you are breast-feeding. It is not known if IMJUDO passes into human breast milk. 
You may be advised to not breast-feed during treatment and for at least 3 months after your last dose.
Driving and using machines
IMJUDO is not likely to affect your driving or use of machines. However, if you have side effects that 
affect your ability to concentrate and react, be careful when driving or operating machines.
IMJUDO has a low sodium content 
IMJUDO contains less than 1 mmol sodium (23 mg) in each dose, that is to say essentially sodium-
free.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take imjudo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take imjudo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>IMJUDO will be given to you in a hospital or clinic under the supervision of an experienced doctor.
Your doctor will give you IMJUDO as a drip into your vein (infusion) lasting about an hour.
It is given in combination with durvalumab for liver cancer.
The recommended dose</p>
<p>If you weigh 40 kg or more, the dose is 300 mg as a one-time single dose.</p>
<p>If you weigh less than 40 kg, the dose will be 4 mg per kg of your body weight.
When IMJUDO is given in combination with durvalumab for your liver cancer, you will be given 
IMJUDO first, then durvalumab. 
It is given in combination with durvalumab and chemotherapy for lung cancer.
The recommended dose: </p>
<p>If you weigh 34 kg or more the dose is 75 mg every 3 weeks.</p>
<p>If you weigh less than 34 kg, the dose will be 1 mg per kg of your body weight every 3 weeks.
You will usually have a total of 5 doses of IMJUDO. The first 4 doses are given in week 1, 4, 7 and
10. The fifth dose is usually then given 6 weeks later, in week 16. Your doctor will decide exactly how 
many treatments you need.
When IMJUDO is given in combination with durvalumab and chemotherapy, you will be given 
IMJUDO first then durvalumab and then chemotherapy. 
If you miss an appointment
It is very important that you do not miss a dose of this medicine. If you miss an appointment, call your 
doctor straight away to reschedule your appointment.
If you have any further questions about your treatment, ask your doctor.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
When you get IMJUDO, you can have some serious side effects. See section 2 for a detailed list of 
these.
Talk to your doctor straight away if you get any of the following side effects that have been reported 
in a clinical study with patients receiving IMJUDO in combination with durvalumab.
The following side effects have been reported in clinical trials in patients taking IMJUDO in 
combination with durvalumab: 
Very common (may affect more than 1 in 10 people)
  underactive thyroid gland that can cause tiredness or weight gain
  cough
  diarrhoea
  stomach pain
  abnormal liver tests (aspartate aminotransferase increased; alanine aminotransferase increased)
  skin rash
  itchiness
  fever
  swelling of legs (oedema peripheral)
Common (may affect up to 1 in 10 people)
  infections of the upper respiratory tract 
  lung infection (pneumonia)
  flu-like illness
  tooth and mouth soft tissue infections
  overactive thyroid gland that can cause fast heart rate or weight loss
  inflammation of the thyroid gland (thyroiditis)
  decreased secretion of hormones produced by the adrenal glands that can cause tiredness
  inflammation of the lungs (pneumonitis)
  abnormal pancreas function tests 
  inflammation of the gut or intestine (colitis)
  inflammation of the pancreas (pancreatitis)
  inflammation of the liver (hepatitis)
  inflammation of the skin
  night sweats 
  muscle pain (myalgia)
  abnormal kidney function test (blood creatinine increased)
  painful urination (dysuria)
  reaction to the infusion of the medicine that can cause fever or flushing
Uncommon (may affect up to 1 in 100 people)
  fungal infection in the mouth
  underactive pituitary gland; inflammation of pituitary gland
  a condition in which the muscles become weak and there is a rapid fatigue of the muscles 
(myasthenia gravis)
  inflammation of the membrane around the spinal cord and brain (meningitis)
  inflammation of the heart (myocarditis)
  hoarse voice (dysphonia)
  scarring of lung tissue 
  blistering of the skin
  inflammation of the muscles (myositis)
  inflammation of the muscles and vessels
  inflammation of the kidneys (nephritis) that can decrease the amount of your urine
Other side effects that have been reported with frequency not known (cannot be estimated from 
the available data)
  low number of platelets with signs of excessive bleeding and bruising (immune 
thrombocytopenia)
  diabetes insipidus
  type 1 diabetes mellitus
  inflammation of the nerves (Guillain-Barr  syndrome)
  inflammation of the brain (encephalitis)
  hole in the bowel (intestinal perforation)
  inflammation of the bladder (cystitis). Signs and symptoms may include frequent and/or painful 
urination, urge to pass urine, blood in urine, pain or pressure in lower abdomen.
The following side effects have been reported in clinical trials in patients taking IMJUDO in 
combination with durvalumab and platinum-based chemotherapy: 
Very common (may affect more than 1 in 10 people)
  infections of the upper respiratory tract
  lung infection (pneumonia)
  low number of red blood cells
  low number of white blood cells
  low number of platelets
  underactive thyroid gland that can cause tiredness or weight gain
  decrease in appetite
  cough
  nausea
  diarrhoea
  vomiting
  constipation
  abnormal liver tests (aspartate aminotransferase increased; alanine aminotransferase increased)
  hair loss
  skin rash
  itchiness 
  joint pain (arthralgia)
  feeling tired or weak
  fever
Common (may affect up to 1 in 10 people)
  flu-like illness
  fungal infection in the mouth
  low number of white blood cells with signs of fever
  low number of red blood cells, white blood cells, and platelets (pancytopenia)
  overactive thyroid gland that can cause fast heart rate or weight loss
  decreased levels of hormones produced by the adrenal glands that can cause tiredness
  underactive pituitary gland; inflammation of pituitary gland
  inflammation of thyroid gland (thyroiditis)
  inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms 
and legs (neuropathy peripheral)
  inflammation of the lungs (pneumonitis)
  hoarse voice (dysphonia)
  inflammation of the mouth or lips
  abnormal pancreas function tests 
  stomach pain
  inflammation of the gut or intestine (colitis)
  inflammation of the pancreas (pancreatitis)
  inflammation of the liver that can cause nausea or feeling less hungry (hepatitis)
  muscle pain (myalgia)
  abnormal kidney function tests (blood creatinine increased)
  painful urination (dysuria)
  swelling of legs (oedema peripheral)
  reaction to the infusion of the medicine that can cause fever or flushing
Uncommon (may affect up to 1 in 100 people)
  tooth and mouth soft tissue infections
  low number of platelets with signs of excessive bleeding and bruising (immune 
thrombocytopenia)
  diabetes insipidus
  type 1 diabetes mellitus
  inflammation of the brain (encephalitis)
  inflammation of the heart (myocarditis)
  scarring of lung tissue 
  blistering of the skin
  night sweats
  inflammation of the skin
  inflammation of the muscle (myositis)
  inflammation of the muscles and vessels
  inflammation of the kidneys (nephritis) that can decrease the amount of your urine
  inflammation of the bladder (cystitis). Signs and symptoms may include frequent and/or painful 
urination, urge to pass urine, blood in urine, pain or pressure in lower abdomen.
Other side effects that have been reported with frequency not known (cannot be estimated from 
the available data)
  a condition in which the muscles become weak and there is a rapid fatigue of the muscles 
(myasthenia gravis)
  inflammation of the nerves (Guillain-Barr  syndrome)
  inflammation of the membrane around the spinal cord and brain (meningitis)
  hole in the bowel (intestinal perforation)
Talk to your doctor straight away if you get any of the side effects listed above.
Reporting of side effects
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in 
this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store imjudo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store imjudo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>IMJUDO will be given to you in a hospital or clinic and the healthcare professional will be responsible 
for its storage.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP.
The expiry date refers to the last day of that month.
Store in a refrigerator (2  C - 8  C).
Do not freeze. 
Store in the original package in order to protect from light.
Do not use if this medicine is cloudy, discoloured or contains visible particles.
Do not store any unused portion of the infusion solution for re-use. Any unused medicine or waste 
material should be disposed of in accordance with local requirements.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What IMJUDO contains
The active substance is tremelimumab.
Each ml of concentrate for solution for infusion contains 20 mg of tremelimumab.
One vial contains either 300 mg of tremelimumab in 15 ml of concentrate or 25 mg of tremelimumab
in 1.25 ml of concentrate.
The other ingredients are: histidine, histidine hydrochloride monohydrate, trehalose dihydrate, 
disodium edetate dihydrate (see section 2  IMJUDO has a low sodium content ), polysorbate 80 and 
water for injections.
What IMJUDO looks like and contents of the pack
IMJUDO concentrate for solution for infusion (sterile concentrate) is a preservative-free, clear to 
slightly opalescent, colourless to slightly yellow solution, free from visible particles.
It is available in packs containing either 1 glass vial of 1.25 ml of concentrate or 1 glass vial of 15 ml
of concentrate.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
AstraZeneca AB
SE-151 85 S dert lje
Sweden
Manufacturer
AstraZeneca AB
G rtunav gen
SE-152 57 S dert lje
Sweden
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
AstraZeneca S.A./N.V.
Tel: +32 2 370 48 Lietuva
UAB AstraZeneca Lietuva
Tel: +370 5 2660 </p>
<p>.: +359 24455Luxembourg/Luxemburg
AstraZeneca S.A./N.V.
T l/Tel: +32 2 370 48  esk  republika
AstraZeneca Czech Republic s.r.o.
Tel: +420 222 807 Magyarorsz g
AstraZeneca Kft.
Tel.: +36 1 883 6Danmark
AstraZeneca A/S
Tlf: +45 43 66 64 Malta
Associated Drug Co. Ltd
Tel: +356 2277 8Deutschland
AstraZeneca GmbH
Tel: +49 40 809034Nederland
AstraZeneca BV
Tel: +31 79 363 2Eesti
AstraZeneca 
Tel: +372 6549 Norge
AstraZeneca AS
Tlf: +47 21 00 64<br />
AstraZeneca A.E.
 : +30 210 6871 sterreich
AstraZeneca  sterreich GmbH
Tel: +43 1 711 31 0
Espa a
AstraZeneca Farmac utica Spain, S.A.
Tel: +34 91 301 91 Polska
AstraZeneca Pharma Poland Sp. z o.o.
Tel.: +48 22 245 73 France
AstraZeneca
T l: +33 1 41 29 40 Portugal
AstraZeneca Produtos Farmac uticos, Lda.
Tel: +351 21 434 61 Hrvatska
AstraZeneca d.o.o.
Tel: +385 1 4628 Rom nia
AstraZeneca Pharma SRL
Tel: +40 21 317 60 Ireland
AstraZeneca Pharmaceuticals (Ireland) 
DAC
Tel: +353 1609 7Slovenija
AstraZeneca UK Limited
Tel: +386 1 51 35  sland
Vistor hf.
S mi: +354 535 7Slovensk  republika
AstraZeneca AB, o.z.
Tel: +421 2 5737 7Italia
AstraZeneca S.p.A.
Tel: +39 02 00704Suomi/Finland
AstraZeneca Oy
Puh/Tel: +358 10 23  </p>
<p>: +357 22490Sverige
AstraZeneca AB
Tel: +46 8 553 26 Latvija
SIA AstraZeneca Latvija
Tel: +371 67377United Kingdom (Northern Ireland)
AstraZeneca UK Ltd
Tel: +44 1582 836 This leaflet was last revised in 
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      





Instance: mp6d641aa5ef0fae66233e33e585fa5fd8
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product IMJUDO 20 mg/ml concentrate for solution for infusion."
Description: "IMJUDO 20 mg/ml concentrate for solution for infusion."
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1713/001 25 mg vial"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "IMJUDO in combination with durvalumab is indicated for the first line treatment of adults with"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "IMJUDO 20 mg/ml concentrate for solution for infusion."
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"





                      
Instance: bundlepackageleaflet-en-7abe5e4c0a96659ff75905a068c8e8d2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for imjudo Package Leaflet for language en"
Description: "ePI document Bundle for imjudo Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "EU/1/22/1713/001 25 mg vial"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-7abe5e4c0a96659ff75905a068c8e8d2"
* entry[0].resource = composition-en-7abe5e4c0a96659ff75905a068c8e8d2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6d641aa5ef0fae66233e33e585fa5fd8"
* entry[=].resource = mp6d641aa5ef0fae66233e33e585fa5fd8
                            
                      